Coronary heart disease
Conditions
Interventions
experimental group:POT and its related techniques(POT-kissing-POT and POT-side-POT)
control group:OOT technique
Sponsors
Union Hospital Affiliated to Fujian Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged > 18 and 2.5 mm and the side-branch > 2.25 mm by visually angiographic estimation; 4. The lesion is suitable for PCI (if the left main trunk bifurcated lesion, SYNTAX score <= 32), and if necessary, the lesion is suitable for double stent implantation; 5. Patients willing to participating and following up; 6. Patients (or legal guardian) understanding the trial protocol and requirement with written consent.
Exclusion criteria
Exclusion criteria: 1. Chronic total occlusion with either of branches unable to recanalization, severely calcified bifurcation lesion requiring rotablation; 2. Patients Intolerance to dual-antiplatelet therapy; 3. Patients with obvious hemopoietic system abnormalities, for instances, plt 700*10^9/L, white count 5 URL)or renal dysfunction (eGR F> 30ml/min/1.73m2), congestive heart failure (NYHA > III) etc. 6. Severe illness with life expectance of <= 12 months, for instances, cancers, other end-stage deceases; 7. Women with or planning to pregnancy; 8. Patients with contraindications or allergies to the stent platforms or the associated medications, for instances, stent eluting drugs, stainless steel or alloy, aspirin, P2Y12 inhibitors, contrast agents, etc.; 9. Patients participating another drug or instrument ongoing trial, or planning to participate another drug or instrument trial within 12 month post-procedurally.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the composite rate of the target lesion failure (TLF) including cardiac death, myocardial infarction (Q- or non-Q-wave) and ischemic target lesion revascularization (iTLR).; | — |
Secondary
| Measure | Time frame |
|---|---|
| acute loss side branch during procedure;Emergency target lesions revascularization and acute in-stent thrombosis (IST) during perioperative or hospitalization;;Procedure-related myocardial necrotic biomarkers release and elevation according to the third universal definition of myocardial infarction.;The incidence of major adverse cardiovascular events (MACE) 12 months after PCI procedure;, including cardiac death, myocardial infarction (Q wave or non-Q wave), in-stent thrombosis (IST) and ischemic target lesion revascularization (iTLR);The rate of in-stent and in-segment restenosis of the MB and SB 12 months after PCI procedure;All-cause death, myocardial infarction and any vascular remodeling (including target lesions, target and non-target vascular revascularization) 12 months after PCI procedure;ARC defined in-stent thrombosis (IST) including acute, subacute, late and very late IST;Cardiac function graded by the New York Heart Association (NYHA);Stable angina grading by Canadian Cardiovascular Society (CCS) or unstable angina by Braunwald; | — |
Countries
China
Contacts
Public ContactChen Lianglong
Union Hospital Affiliated to Fujian Medical University
Outcome results
None listed